Antimicrobial practice Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital

In recent years ‘switch therapy’ has been advocated: short intravenous antibiotic therapy, for 2‐3 days, followed by oral treatment for the remainder of the course. Little is known about the number of patients that could benefit from early switch therapy and the consequences of introducing this strategy in everyday practice. We prospectively registered all antibiotic courses on wards for Internal Medicine, Surgery, and Pulmonology during a 2 month period, before (n 362, inventorial phase) and after (n 281, implementation phase) the introduction of guidelines for switching therapy. Approximately 40% of all patients who started on iv antibiotics were candidates for an early iv‐oral switch. During the inventorial phase, 54% (52/97) of eligible patients were switched to oral treatment, after a median of 6 days (range 2‐28 days). After implementation of the guidelines, this percentage rose to 83% (66/80) (difference 29%, 95% CI 16‐42%; P 6000 per year. This means a potential annual reduction of dfl.60,000 (c. US$30,000) of administratio n costs. The potential savings in purchase costs of the antibiotics were dfl.54,000 (US$27,000) annually. In conclusion, a substantial number of patients starting on iv antibiotics were candidates for an early iv‐oral switch. The guidelines were well accepted by the physicians and substantial savings in costs and nursing time were achieved.

[1]  J. Meer,et al.  Cost of hospital antimicrobial chemotherapy , 1991, Pharmaceutisch Weekblad.

[2]  D. Wennberg,et al.  Antibiotic Optimization: An Evaluation of Patient Safety and Economic Outcomes , 1997 .

[3]  R. Macgregor,et al.  Oral administration of antibiotics: a rational alternative to the parenteral route. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  N. Halpern,et al.  A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. , 1996, Chest.

[5]  J. Hamilton-miller,et al.  Switch therapy: the theory and practice of early change from parenteral to non-parenteral antibiotic administration. , 1996, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  Michael H. Miller,et al.  Sequential Parenteral and Oral Ciprofloxacin Regimen versus Parenteral Therapy for Bacteremia: A Pharmacoeconomic Analysis , 1996, The Annals of pharmacotherapy.

[7]  David Classen,et al.  Implementing Antibiotic Practice Guidelines through Computer-Assisted Decision Support: Clinical and Financial Outcomes , 1996, Annals of Internal Medicine.

[8]  I. Lauder,et al.  Hospital antibiotic prescribing successfully modified by 'immediate concurrent feedback'. , 1996, British journal of clinical pharmacology.

[9]  F. Vogel Sequential therapy in the hospital management of lower respiratory infections. , 1995, The American journal of medicine.

[10]  M. Bergeron,et al.  Sequential antibiotic therapy: Effective cost management and patient care. , 1995, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[11]  A. U. Okpara,et al.  Criteria-based antimicrobial i.v. to oral conversion program. , 1995, Formulary.

[12]  J. Feely,et al.  Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial , 1995, BMJ.

[13]  K. A. Hunter,et al.  Pharmacist-managed intravenous to oral step-down program. , 1995, Clinical therapeutics.

[14]  R. Davis,et al.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections. , 1994, PharmacoEconomics.

[15]  F. Vogel Efficacy and tolerance of cefotaxime followed by oral cefixime versus cefotaxime alone in patients with lower respiratory tract infections , 1994 .

[16]  V L Yu,et al.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. , 1993 .

[17]  J. Meer,et al.  Optimizing antimicrobial therapy. A method for antimicrobial drug use evaluation. , 1992, The Journal of antimicrobial chemotherapy.

[18]  T. Bergan,et al.  Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. , 1992, Scandinavian journal of infectious diseases.

[19]  J. Feely,et al.  Hospital formularies: need for continuous intervention. , 1990, BMJ.

[20]  C. Cox Brief report: Sequential intravenous and oral ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections , 1989 .

[21]  J. Plouffe,et al.  Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. , 1989, The American journal of medicine.

[22]  F. Jacobs,et al.  Randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of gram-negative septicemia. , 1989, The American journal of medicine.

[23]  B. Régnier [Comparative study of intravenous ceftriaxone followed by oral cefixime versus ceftriaxone alone in the treatment of severe upper urinary tract infections]. , 1989, Presse medicale.

[24]  F. Khan,et al.  Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. , 1989, Chest.